Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.49 |
| ▸ | FNTB | P49356 | 6/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213322 | 1.00 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL907397 | 0.85 | FNTA (0.47) | FNTAFNTBPGGT1B | |
| SCHEMBL3382819 | 0.82 | ALPI (0.42) | FNTAFNTBPGGT1B | |
| Formic Acid SCHEMBL27865482 | 0.82 | FNTA (0.52) | FNTAFNTBPGGT1B | |
| Methionine SCHEMBL2821984 | 0.81 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL907360 | 0.81 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL3646826 | 0.81 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL907359 | 0.81 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| Racemethionine SCHEMBL16758759 | 0.81 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL10696437 | 0.80 | FNTA (0.60) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072447-A1 | ENHANCED ORAL TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGANOSTIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-21 | — | — | US | claimed |
| US-7740882-B2 | polyoxyethylene glycol having multiple functional groups, at least one of which is covalently bound to a therapeutic or diagnostic agent (peptide) , and a cell uptake promoter (formyl-met-leu-phe)covalently bound to the therapeutic or diagnostic agent; conjugates; pharmacokinetic; bioavailability | RAMANATHAN SRINIVASAN | 2010-06-22 | — | — | US | claimed |
| US-20230349890-A1 | METHOD FOR DETERMINATION OF BASOPHIL ACTIVATION AND KITS THEREFORE | FORSCHUNGZENTRUM BORSTEL LEIBNIZ-LUNGENZENTRUM (DE) | 2023-11-02 | — | — | US | disclosed |
| EP-4200610-A1 | METHOD FOR DETERMINATION OF BASOPHIL ACTIVATION AND KITS THEREFORE | Forschungszentrum Borstel, Leibniz Lungenzentrum (DE) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022038217-A1 | METHOD FOR DETERMINATION OF BASOPHIL ACTIVATION AND KITS THEREFORE | FORSCHUNGSZENTRUM BORSTEL LEIBNIZ-LUNGENZENTRUM (DE) | 2022-02-24 | — | — | WO | disclosed |
| EP-3957992-A1 | METHOD FOR DETERMINATION OF BASOPHIL ACTIVATION AND KITS THEREFORE | Forschungszentrum Borstel, Leibniz Lungenzentrum (DE) | 2022-02-23 | — | — | EP | disclosed |
| CN-107050029-A | Application of medicinal composition in preparing medicinal composition for treating skin itch | 怀特生技新药股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-8709758-B2 | Methods and compositions for inhibition of neutrophil exocytosis | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20110178020-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF NEUTROPHIL EXOCYTOSIS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010014608-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF NEUTROPHIL EXOCYTOSIS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| EP-1575506-A4 | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-BETA INHIBITORS | SCIOS INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1575506-A2 | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-BETA INHIBITORS | Scios, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20040146509-A1 | Methods for improvement of lung function using TGF-beta inhibitors | SCIOS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004010929-A2 | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS | SCIOS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-1997026913-A1 | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0303250-A2 | Novel pyrazinoxide compound of NF-1616-904 and a pharmaceutical composition containing the same and a process for its preparation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040146509-A1 | Methods for improvement of lung function using TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | FNTA 905/4885FNTB 140/4885PGGT1B 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.